The Swiss firm, which this week filed a melanoma combination drug for US approval, spent $10bn on research into new products, ahead of rivals such as Novartis, which spent $9.8bn and the $8.2bn spent by Johnson & Johnson (J&J).
{iframe}http://www.pmlive.com/pharma_news/roche_leads_pharma_r_and_d_spend_for_2013_625281{/iframe}